tenatumomab
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1991 (NCT00002753)
Timeline
1990s
- Jan 1, 1991
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSD4E1UP3RMV ↗
- ChEMBLCHEMBL2109582 ↗
- ChEMBLCHEMBL1743077 ↗
Also known as
- 81c6
- 81c6
- 81c6 131i
- st-2146
- tenatumomab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003461 | Phase 1/Phase 2 (Phase 2) | Feb 1, 1998 | Duke University, National Cancer Institute (NCI) |
| NCT00003478 | Phase 1/Phase 2 (Phase 2) | Oct 1, 1997 | Duke University, National Cancer Institute (NCI) |
| NCT00003484 | Phase 1 | Sep 1, 1997 | Duke University, National Cancer Institute (NCI) |
| NCT00002752 | Phase 1/Phase 2 (Phase 2) | Feb 1, 1993 | Duke University |
| NCT00002753 | Phase 1 | Nov 1, 1991 | Duke University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 5 | 5 | 2 | 1991 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1997 |
2 organizations
Page 1 / 1